Published in J Clin Oncol on December 28, 2010
The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS One (2013) 0.90
External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement. PLoS One (2011) 0.89
Molecular tests as prognostic factors in breast cancer. Virchows Arch (2014) 0.88
Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One (2012) 0.88
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat (2014) 0.85
Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis (2013) 0.85
Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis. Am J Surg Pathol (2013) 0.79
Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade? PLoS One (2013) 0.78
HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ (2010) 2.10
Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun (2007) 2.06
Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem (2009) 1.83
Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol (2011) 1.73
Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology (2012) 1.64
Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol (2004) 1.57
Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. Urology (2002) 1.53
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Improved lymph node harvest from resected colon cancer specimens did not cause upstaging from TNM stage II to III. World J Surg (2011) 1.47
Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol (2004) 1.46
Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer (2008) 1.39
[Hypotension and oxygen saturation fall in a woman during sentinel lymph node biopsy]. Tidsskr Nor Laegeforen (2011) 1.39
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer (2007) 1.37
Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J (2004) 1.30
Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol (2005) 1.26
Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol (2007) 1.23
Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol (2007) 1.22
Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol (2003) 1.20
Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene (2003) 1.20
Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer (2013) 1.20
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat (2008) 1.12
Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol (2002) 1.12
Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol (2005) 1.08
Circadian variations in clock gene expression of human bone marrow CD34+ cells. J Biol Rhythms (2007) 1.07
Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. Eur J Cancer (2008) 1.07
High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study. World J Surg Oncol (2010) 1.04
Benign peritoneal cystic mesothelioma. World J Surg (2006) 1.03
Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol (2010) 1.03
Confocal DNA cytometry: a contour-based segmentation algorithm for automated three-dimensional image segmentation. Cytometry (2002) 1.01
Chromosomal changes in relation to clinical outcome in larynx and pharynx squamous cell carcinoma. Cell Oncol (2005) 1.01
[Appendiceal mucinous cystadenoma]. Tidsskr Nor Laegeforen (2005) 0.99
Epidemiology of gastrointestinal stromal tumours: single-institution experience and clinical presentation over three decades. Cancer Epidemiol (2011) 0.99
Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol (2011) 0.98
Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Hum Pathol (2008) 0.95
Dietary supplementation of krill oil attenuates inflammation and oxidative stress in experimental ulcerative colitis in rats. Scand J Gastroenterol (2011) 0.95
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat (2013) 0.95
Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene (2005) 0.95
Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer (2005) 0.94
Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol (2010) 0.93
Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat (2008) 0.93
The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS One (2013) 0.90
Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer. Pol J Pathol (2013) 0.89
Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. Neoplasia (2010) 0.89
The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3. J Clin Pathol (2011) 0.89
Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest (2006) 0.89
Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. Diagn Mol Pathol (2012) 0.89
LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer. Cell Oncol (2009) 0.89
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther (2010) 0.89
Adenomyoepitheliomatous lesions of the mammary glands in transgenic mice with targeted PLAG1 overexpression. Int J Cancer (2008) 0.88
Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One (2012) 0.88
Cervical intraepithelial neoplasia grade 3 lesions can regress. APMIS (2007) 0.88
Prognostic relevance of androgen receptor detection in operable breast cancer. J Surg Oncol (2008) 0.87
Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer. Appl Immunohistochem Mol Morphol (2008) 0.87
Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod Pathol (2008) 0.86
Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer (2010) 0.86
Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res (2005) 0.86
Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance after resection. Cancer (2009) 0.86
Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome. Clin Transl Oncol (2012) 0.86
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int (2011) 0.85
Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas. Oncogene (2005) 0.85
Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol (2012) 0.85